Peptides Similar to Adipotide

Peptides Related to Adipotide#

Adipotide (FTPP) occupies a unique position in the landscape of anti-obesity research compounds due to its distinctive mechanism of targeted vascular destruction. This section compares adipotide with other peptide-based approaches to obesity treatment, highlighting the mechanistic differences and relative evidence bases.

Mechanism Comparison#

Vascular Targeting vs. Receptor-Mediated Approaches#

Adipotide stands apart from nearly all other anti-obesity peptides in that it operates through direct tissue destruction rather than receptor-mediated signaling. While compounds like cagrilintide and GLP-1 receptor agonists modulate appetite and metabolic pathways through reversible receptor interactions, adipotide induces irreversible apoptosis in adipose vasculature.

This fundamental difference has several implications:

• Reversibility: Most peptide-based anti-obesity treatments produce effects that reverse upon discontinuation. Adipotide's effects are largely irreversible once adipose vasculature is destroyed, though adipose tissue can regenerate over time.
• Continuous dosing: Receptor-mediated approaches typically require ongoing administration. Adipotide treatment is finite, with effects persisting after treatment cessation.
• Safety profile: Reversible receptor-mediated approaches generally have more favorable safety profiles compared to tissue-destructive mechanisms.

AOD-9604#

AOD-9604 is a modified fragment (amino acids 177-191) of human growth hormone that has been investigated for its lipolytic and anti-lipogenic properties. Unlike adipotide, AOD-9604 works by stimulating fat breakdown and inhibiting fat formation through interactions with the beta-3 adrenergic receptor pathway, without affecting growth or insulin levels.

AOD-9604 has progressed further in clinical development than adipotide, having been tested in human Phase IIb clinical trials for obesity. While human trials showed the compound was safe and well-tolerated, the efficacy results were modest, and the compound has not achieved regulatory approval for obesity treatment.

The key advantage of AOD-9604 over adipotide is its established safety profile in humans and its reversible mechanism of action. The key limitation is its modest efficacy compared to the dramatic fat reduction observed with adipotide in animal models.

Cagrilintide#

Cagrilintide (AM833) is a long-acting amylin analog that represents a newer approach to obesity pharmacotherapy. It works by activating amylin receptors in the brain, leading to reduced appetite, delayed gastric emptying, and improved metabolic parameters. When combined with semaglutide (a GLP-1 receptor agonist), the combination (CagriSema) has shown over 20% weight loss in Phase 3 clinical trials.

Compared to adipotide, cagrilintide offers several advantages: it has extensive human clinical data, a well-characterized safety profile, a reversible mechanism of action, and regulatory support for clinical development. However, cagrilintide requires ongoing weekly injections for sustained effect, whereas adipotide's effects persist after treatment cessation.

The evidence base for cagrilintide is substantially stronger than for adipotide, with multiple Phase 2 and Phase 3 clinical trials versus exclusively preclinical animal studies.

GLP-1 Receptor Agonists#

GLP-1 receptor agonists (such as semaglutide and liraglutide) represent the current clinical standard for peptide-based obesity treatment. These compounds work through multiple mechanisms including appetite suppression, delayed gastric emptying, enhanced insulin secretion, and reduced glucagon release.

FDA-approved GLP-1 agonists have demonstrated 15-20% weight loss in clinical trials and have extensive real-world safety and efficacy data. Their mechanism is entirely different from adipotide, operating through reversible receptor interactions rather than tissue destruction.

The primary limitation of GLP-1 agonists compared to adipotide's theoretical advantage is weight regain upon discontinuation, which can approach complete reversal within 1-2 years. Adipotide's irreversible fat tissue destruction could theoretically provide more durable weight loss, though this remains unproven in long-term studies.

Summary Comparison Table#

Clinical Implications#

The comparison highlights that adipotide's unique mechanism produces dramatic preclinical results but faces significant translational challenges. The compounds with proven clinical utility (GLP-1 agonists, and potentially cagrilintide) operate through fundamentally different, reversible mechanisms with better safety profiles. Adipotide may be most relevant as a research tool for understanding adipose tissue biology rather than as a near-term clinical candidate.

Related Reading#

• Adipotide overview and research guide
• Adipotide research evidence
• Adipotide dosing protocols